BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1070 related articles for article (PubMed ID: 32084293)

  • 1. A synopsis of prostate organoid methodologies, applications, and limitations.
    Gleave AM; Ci X; Lin D; Wang Y
    Prostate; 2020 May; 80(6):518-526. PubMed ID: 32084293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of conditional reprogramming cell, patient derived xenograft and organoid for drug screening for individualized prostate cancer therapy: Current and future perspectives (Review).
    Cao J; Chan WC; Chow MSS
    Int J Oncol; 2022 May; 60(5):. PubMed ID: 35322860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Organoid cultures derived from patients with advanced prostate cancer.
    Gao D; Vela I; Sboner A; Iaquinta PJ; Karthaus WR; Gopalan A; Dowling C; Wanjala JN; Undvall EA; Arora VK; Wongvipat J; Kossai M; Ramazanoglu S; Barboza LP; Di W; Cao Z; Zhang QF; Sirota I; Ran L; MacDonald TY; Beltran H; Mosquera JM; Touijer KA; Scardino PT; Laudone VP; Curtis KR; Rathkopf DE; Morris MJ; Danila DC; Slovin SF; Solomon SB; Eastham JA; Chi P; Carver B; Rubin MA; Scher HI; Clevers H; Sawyers CL; Chen Y
    Cell; 2014 Sep; 159(1):176-187. PubMed ID: 25201530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Progress in prostate cancer study: 3D cell culture enables the ex vivo reproduction of tumor characteristics].
    Tostivint V; Racaud-Sultan C; Roumiguié M; Soulié M; Gamé X; Beauval JB
    Presse Med; 2017 Oct; 46(10):954-965. PubMed ID: 28967525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening.
    Beshiri ML; Tice CM; Tran C; Nguyen HM; Sowalsky AG; Agarwal S; Jansson KH; Yang Q; McGowen KM; Yin J; Alilin AN; Karzai FH; Dahut WL; Corey E; Kelly K
    Clin Cancer Res; 2018 Sep; 24(17):4332-4345. PubMed ID: 29748182
    [No Abstract]   [Full Text] [Related]  

  • 6. Advantages and limitations of 3D organoids and ex vivo tumor tissue culture in personalized medicine for prostate cancer.
    Mickova A; Morong M; Levková M; Kurfúrstová D; Kharaishvili G; Überall I; Student V; Student V; Drapela S; Soucek K; Bouchal J
    Klin Onkol; 2022; 35(6):473-481. PubMed ID: 36513514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Organoids: An Emerging Precision Medicine Model for Prostate Cancer Research.
    Waseem M; Wang BD
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of Organoid Models in Prostate Cancer Research.
    Zhou L; Zhang C; Zhang Y; Shi C
    Front Oncol; 2021; 11():736431. PubMed ID: 34646778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate cancer patient-derived organoids: detailed outcome from a prospective cohort of 81 clinical specimens.
    Servant R; Garioni M; Vlajnic T; Blind M; Pueschel H; Müller DC; Zellweger T; Templeton AJ; Garofoli A; Maletti S; Piscuoglio S; Rubin MA; Seifert H; Rentsch CA; Bubendorf L; Le Magnen C
    J Pathol; 2021 Aug; 254(5):543-555. PubMed ID: 33934365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of Prostate Cancer Models for Preclinical Study: Advantages and Limitations of Cell Lines, Patient-Derived Xenografts, and Three-Dimensional Culture of Patient-Derived Cells.
    Namekawa T; Ikeda K; Horie-Inoue K; Inoue S
    Cells; 2019 Jan; 8(1):. PubMed ID: 30669516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering prostate cancer in vitro: what does it take?
    Buskin A; Scott E; Nelson R; Gaughan L; Robson CN; Heer R; Hepburn AC
    Oncogene; 2023 Aug; 42(32):2417-2427. PubMed ID: 37438470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viability Analysis and High-Content Live-Cell Imaging for Drug Testing in Prostate Cancer Xenograft-Derived Organoids.
    Van Hemelryk A; Erkens-Schulze S; Lim L; de Ridder CMA; Stuurman DC; Jenster GW; van Royen ME; van Weerden WM
    Cells; 2023 May; 12(10):. PubMed ID: 37408211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment and Analysis of Three-Dimensional (3D) Organoids Derived from Patient Prostate Cancer Bone Metastasis Specimens and their Xenografts.
    Lee S; Burner DN; Mendoza TR; Muldong MT; Arreola C; Wu CN; Cacalano NA; Kulidjian AA; Kane CJ; Jamieson CAM
    J Vis Exp; 2020 Feb; (156):. PubMed ID: 32065165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine.
    Pamarthy S; Sabaawy HE
    Mol Cancer; 2021 Sep; 20(1):125. PubMed ID: 34587953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Organoids: An intermediate modeling platform in precision oncology.
    Jin MZ; Han RR; Qiu GZ; Ju XC; Lou G; Jin WL
    Cancer Lett; 2018 Feb; 414():174-180. PubMed ID: 29174804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of Tumor Organoids from Genetically Engineered Mouse Models of Prostate Cancer.
    Wadosky KM; Wang Y; Zhang X; Goodrich DW
    J Vis Exp; 2019 Jun; (148):. PubMed ID: 31259888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions.
    Fong EL; Wan X; Yang J; Morgado M; Mikos AG; Harrington DA; Navone NM; Farach-Carson MC
    Biomaterials; 2016 Jan; 77():164-72. PubMed ID: 26599623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-derived xenografts and organoids model therapy response in prostate cancer.
    Karkampouna S; La Manna F; Benjak A; Kiener M; De Menna M; Zoni E; Grosjean J; Klima I; Garofoli A; Bolis M; Vallerga A; Theurillat JP; De Filippo MR; Genitsch V; Keller D; Booij TH; Stirnimann CU; Eng K; Sboner A; Ng CKY; Piscuoglio S; Gray PC; Spahn M; Rubin MA; Thalmann GN; Kruithof-de Julio M
    Nat Commun; 2021 Feb; 12(1):1117. PubMed ID: 33602919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling of pancreatic cancer biology: transcriptomic signature for 3D PDX-derived organoids and primary cell line organoid development.
    Nelson SR; Zhang C; Roche S; O'Neill F; Swan N; Luo Y; Larkin A; Crown J; Walsh N
    Sci Rep; 2020 Feb; 10(1):2778. PubMed ID: 32066753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges, applications and future directions of precision medicine in prostate cancer - the role of organoids and patient-derived xenografts.
    Joshi A; Roberts MJ; Alinezhad S; Williams ED; Vela I
    BJU Int; 2020 Jul; 126(1):65-72. PubMed ID: 32383524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.